Global Leading Market Research Publisher QYResearch announces the release of its latest report “Short-acting Bronchodilators – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Short-acting Bronchodilators market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Asthma and COPD patients require rapid relief during acute attacks – but delayed or inadequate rescue medication can lead to severe exacerbations. Short-acting bronchodilators (SABAs/SAMAs) solve this with fast-acting (3–5 minute onset) bronchodilation via metered-dose inhalers, using APIs like albuterol, levalbuterol, and ipratropium. Key drivers include respiratory disease prevalence, emergency preparedness, and generic availability.
The global market for Short-acting Bronchodilators was estimated to be worth US$ 4,489 million in 2025 and is projected to reach US$ 5,932 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, the average global price was about US$ 19.6 per unit, with total sales reaching approximately 220 million units.
Short-acting bronchodilators (SABAs and SAMAs) are critical rescue medications used during acute asthma attacks and COPD exacerbations. Their upstream supply chain involves active pharmaceutical ingredients (APIs) such as albuterol, levalbuterol, and ipratropium, propellants like HFA-134a and HFA-227, and delivery components including aluminum canisters, metering valves, and spray actuators. These key materials are mainly provided by specialized global suppliers such as Linde and Chemours (propellants), as well as Aptar and Lindal (aerosol valves and actuator systems). Due to high technical and regulatory barriers, manufacturers rely on a stable and highly compliant international supply chain. On the downstream side, the primary customers include hospitals, clinics, retail pharmacies, and pharmacy chains, with strong demand in both emergency and home-care scenarios. Leading manufacturers such as GSK, AstraZeneca, Boehringer Ingelheim, and Teva dominate the global market, creating a landscape where branded products and generics coexist.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098340/short-acting-bronchodilators
Market Segmentation & Key Players
The Short-acting Bronchodilators market is segmented as below:
Leading Suppliers: Boehringer Ingelheim, GSK, Teva Pharmaceutical, Prasco Laboratories, Cipla, Lupin Laboratories, Laboratorio Aldo-Union, Polpharma, Jewim Pharmaceutical, Heilongjiang Fulekang Pharmaceutical, Shanghai Pharmaceuticals, Lunan Better Pharmaceutical, China Resources Double Crane Pharmaceutical.
Segment by Type: Albuterol (Salbutamol) | Levalbuterol | Ipratropium | Others
Segment by Application: Asthma | COPD | Others
Exclusive Industry Insights
Discrete pressurized MDI manufacturing: Short-acting bronchodilators are manufactured via pressure-fill process – micronized API suspended in HFA propellant, filled into aluminum canisters with metering valves (50–100μL per actuation). Valve precision critical for dose consistency (±15% per USP).
Technical differentiation – molecule selection:
- Albuterol (68% revenue): Most widely used SABA, 4–6 hour duration, onset 3–5 minutes. Largest segment, multiple generics.
- Levalbuterol (15% revenue): R-isomer of albuterol, fewer cardiac side effects, higher cost. Preferred for sensitive patients.
- Ipratropium (12% revenue): SAMA, slower onset (15 minutes), longer duration (6–8 hours). Often combined with albuterol for COPD.
- Others (5% revenue): Fenoterol, terbutaline (regional markets).
Recent 6-month data (Oct 2025 – Mar 2026):
- Asthma largest application (68% revenue), COPD fastest-growing (CAGR 4.8%).
- Generic albuterol MDIs captured 52% of US market (up from 38% in 2020).
- Propellant transition to low-GWP HFO-1234ze under EU regulation (effective 2026).
User case – Urban health system (US, 1M emergency visits/year): Stocking generic albuterol MDIs in emergency departments and outpatient pharmacies reduced rescue medication cost by 42% (US$ 8.2M annually). Patient outcomes (hospitalization rates, revisit rates) unchanged over 18 months.
Application insights: Asthma (68%) – acute attack relief, exercise-induced bronchospasm prevention. COPD (28%) – acute exacerbation management, adjunct to maintenance therapy. Others (4%) – bronchospasm from other causes.
Key market dynamics:
| Factor | Impact |
|---|---|
| Generic penetration | Increasing (52% US, 65% Europe) |
| Propellant transition | HFA to HFO (2026–2030) |
| GINA guideline updates | Reduced reliance on SABA alone (ICS + SABA preferred) |
| Emerging markets growth | Asia-Pacific 6% CAGR |
Regional snapshot: North America leads with 48% revenue share (higher branded prices). Europe holds 24% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 5.8%), driven by asthma/COPD diagnosis improvement.
Conclusion
The short-acting bronchodilator market is mature but growing, driven by generic expansion, respiratory disease prevalence, and emerging market access. Success depends on propellant transition, valve precision, and cost competitiveness. The projected US$ 5.93 billion market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
